Lisata Therapeutics

Certepetide (LSTA1-P02) is a small-molecule therapeutic candidate developed by LISATA THERAPEUTICS, INC. for the treatment of cholangiocarcinoma, a rare and aggressive biliary tract malignancy. The program is currently in Phase 2 clinical development. As of June 6, 2025, the program remains active, though specific details regarding mechanism of action, molecular target, and recent milestone outcomes are not yet disclosed. Cholangiocarcinoma represents a significant unmet medical need, with limited treatment options and poor prognosis; the competitive landscape includes multiple Phase 3 candidates targeting similar patient populations through diverse mechanisms. LISATA's development strategy positions certepetide within a crowded but clinically important indication. The Phase 2 trial (NCT05712356) is the primary clinical evidence base for the program. Regulatory approval status and projected timelines for advancement to Phase 3 remain undisclosed. The program's advancement will depend on Phase 2 efficacy and safety data, as well as differentiation relative to competitors in advanced development stages.

Cholangiocarcinoma is a rare but highly lethal malignancy with limited therapeutic options and poor overall survival rates. The disease affects approximately 8,000–10,000 patients annually in the United States, with global incidence rising. Current standard-of-care chemotherapy (gemcitabine plus cisplatin) offers modest survival benefit, creating substantial unmet medical need for targeted therapies. The competitive landscape reveals significant pharmaceutical investment in this indication, with multiple Phase 3 programs from established oncology companies (Incyte, AstraZeneca, BridgeBio, Taiho) targeting FGFR and other molecular pathways. Certepetide's Phase 2 status places it earlier in development than most competitors, requiring demonstration of clinical benefit to justify advancement. Market relevance is high: successful cholangiocarcinoma therapies command premium pricing and address a population with few alternatives. LISATA's positioning depends on Phase 2 data quality, safety profile, and evidence of efficacy advantage or improved tolerability relative to Phase 3 competitors. Patient population remains limited but concentrated, enabling focused clinical development and potential accelerated regulatory pathways if early signals are compelling. Commercial significance is moderate to high given the rare disease designation and limited competition at approval, though market size constraints and competitive pressure from advanced-stage programs present material risk to long-term commercial success.

Certepetide is a small-molecule therapeutic candidate. The specific molecular target, mechanism of action, and route of administration are not yet disclosed. Related therapies in development for cholangiocarcinoma include FGFR inhibitors (pemigatinib, BGJ398, TAS-120, E7090), IDH inhibitors (Tibsovo/ivosidenib), and other targeted agents. First approval date and patent expiration are not yet disclosed.

• Modality: Small molecule
• Indication: Cholangiocarcinoma
• Sponsor: LISATA THERAPEUTICS, INC.
• Development Phase: Phase 2
• Target: Not yet disclosed
• Mechanism of Action: Not yet disclosed
• Route of Administration: Not yet disclosed

Regulatory approval status for certepetide is not yet disclosed. No FDA, EMA, PMDA, or NMPA approvals or designations (breakthrough therapy, orphan drug, etc.) are documented in available facts. The program is actively enrolled in Phase 2 clinical trial NCT05712356. Advancement to Phase 3 and regulatory timelines remain undisclosed. Cholangiocarcinoma qualifies for orphan drug designation in major markets, potentially enabling expedited regulatory pathways if clinical data support approval.

Strategic Positioning: Certepetide enters a highly competitive indication with multiple Phase 3 programs from larger, better-resourced competitors. LISATA's Phase 2 status requires rapid advancement and compelling data differentiation to justify continued investment and eventual commercialization.

Competitive Risk: Multiple FGFR inhibitors (pemigatinib, BGJ398, TAS-120) are in Phase 3, with potential approvals within 2–3 years. Certepetide must demonstrate superior efficacy, improved safety, or biomarker-driven patient enrichment to compete. IDH inhibitors (Tibsovo) represent an alternative mechanism already advanced in development.

Clinical Catalysts: Phase 2 data readout will be critical; efficacy signals, safety profile, and biomarker correlations will determine Phase 3 feasibility. Potential accelerated pathways (breakthrough therapy, orphan drug) depend on Phase 2 outcomes.

Future Milestones: Phase 2 completion and data presentation at oncology conferences; Phase 3 initiation decision; potential regulatory interactions with FDA regarding development strategy and endpoints.

Commercial Implications: Cholangiocarcinoma is a rare disease with limited patient population (~8,000–10,000 annually in US), constraining peak sales potential. Market entry will depend on competitive differentiation and pricing relative to approved therapies. LISATA's lack of disclosed partnerships suggests independent development, increasing execution risk.